Fact CheckerSign in

NCT06451029Recruiting

Prevention of Smoking Related Diseases

Integrated Primary and Secondary Prevention of Smoking Related Diseases With Low Dose CT Scan and Circulating Biomarkers, Coupled With Personalised Smoking Cessation Activity

Source: ClinicalTrials.gov · Last updated 29 Nov 2024 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

This is a prospective, observational, monocentric study. This study wants to test if among a smoking cessation intervention, behavioural counselling by video session is related to higher compliance and higher success rate than standard smoking cessation activity (face to face counselling).

Status (registry)
Recruiting
Study type
Observational
Enrollment
189 (estimated)
First submitted
30 May 2024
Start date
11 Jan 2022
Primary completion date
31 Dec 2025
Lead sponsor
Scientific Institute San Raffaele
Diseases
Lung cancer
NCT number
NCT06451029

What you commit to

  • Study type: Observational
  • Planned participants: 189
  • From 11 Jan 2022 to the primary completion date, 31 Dec 2025
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other

  • Not having plans to quit smoking

Who the study is looking for

  • Strong smokers (pack years \>= 20)
  • Over or equal the age of 50
  • Able to sign specific informed consent for the study

Age in the registry: 50 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Scientific Institute Ospedale San Raffaele
Coordinator of this site? Confirm its status
MilanItalyRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.